Skip to content

Effects of Tegileridine, Oliceridine, and Sufentanil on Postoperative Analgesia and Recovery Quality in Elderly Patients Undergoing Laparoscopic Gastrointestinal Tumor Surgery: A Prospective Randomized Controlled Trial

Effects of Tegileridine, Oliceridine, and Sufentanil on Postoperative Analgesia and Recovery Quality in Elderly Patients Undergoing Laparoscopic Gastrointestinal Tumor Surgery: A Prospective Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128905
Enrollment
Unknown
Registered
2026-07-28
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal tumor

Interventions

Sufentanil Group:All patients received patient-controlled intravenous analgesia after the operation. The configuration of the analgesic pump was as follows: sufentanil 2 µg/kg+ flurbiprofen axetil 200
Oliceridine Group:All patients received patient-controlled intravenous analgesia after the operation. The configuration of the analgesia pump was as follows: oxelidine 0.3 mg/kg+ flurbiprofen axetil 2
Tegileridine Group:All patients received patient-controlled intravenous analgesia after the operation. The analgesic pump was configured with tigillidine 0.05 mg/kg+ flurbiprofen axetil 200 mg+ palono

Sponsors

Changzhi people's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 65 to 80 years, male or female, scheduled for elective radical laparoscopic gastrectomy / colectomy / rectal resection for cancer. 2.American Society of Anesthesiologists (ASA) physical status classification I to III, and New York Heart Association (NYHA) cardiac functional classification I to III. 3.Clear consciousness with no communication impairment, capable of cooperating with the completion of the QoR-40 scale, NRS pain score assessment, and study follow-up. 4.Liver and kidney functions, as well as coagulation function, are basically normal (ALT<3 times the upper limit of normal; AST<3 times the upper limit of normal; Cr<133µmol/L; prothrombin time within the normal range of 11-16 seconds). 5.Voluntary provision of signed informed consent and willingness to comply with the entire study protocol and follow-up procedures. 6.Voluntary acceptance of postoperative patient-controlled intravenous analgesia (PCIA).

Exclusion criteria

Exclusion criteria: 1.Known allergy or hypersensitivity to opioid medications such as tegileridine, oliceridine, or sufentanil. 2. Those with severe respiratory dysfunction (severe chronic obstructive pulmonary disease, respiratory failure) and cardiac function grade IV or above; 3. Severe liver and kidney failure (Child-Pugh grade C, serum creatinine clearance rate <15ml/min); 4.Comorbid psychiatric disorders or cognitive impairment that would preclude cooperation with scale-based assessments and follow-up. 5.Preoperative history of chronic pain, or abuse or long-term use of anesthetic, sedative, or analgesic medications. 6.Comorbid coagulation disorders or peptic ulcer disease. 7.Known or suspected gastrointestinal obstruction, including paralytic ileus.

Design outcomes

Primary

MeasureTime frame
Quality of Recovery-40 (QoR-40) scale;

Secondary

MeasureTime frame
Time to first ambulation postoperatively;Doses of intraoperative analgesic agents;Total number of PCA pump demands;Time to first defecation;Number of patients receiving rescue analgesia;length of hospital stay;Time to first flatus;Adverse reaction incidence;Total PCA bolus deliveries;Doses of intraoperative vasoactive agents;Heart Rate;Mean Arterial Pressure;Neutrophil-to-lymphocyte ratio;Numerical Rating Scale;C-reactive protein;

Countries

China

Contacts

Public ContactMa Xiaoyan

Changzhi people's Hospital

66846396@qq.com+86 13223651919

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026